FOCUSED SPRAY JET PRINTING SYSTEM
    73.
    发明公开

    公开(公告)号:US20240269991A1

    公开(公告)日:2024-08-15

    申请号:US18423371

    申请日:2024-01-26

    CPC classification number: B41J2/215

    Abstract: A focused spray jet printing system according to an exemplary embodiment of the present invention may include an atomization unit which atomizes ink by a carrier gas to make generate atomization droplets; a head unit including a virtual impactor which uniformizes sizes of supply atomization droplets ejected from the atomization unit to eject uniform atomization droplets; a focusing unit which is provided in the head unit to focus the uniform atomization droplets introduced into the head unit with sheath gas to spray the uniform atomization droplets onto a substrate; a sheath MFC which supplies the sheath gas, and a valve unit which is selectively connected to any one of an atomization droplet flow path which is formed in the head unit to flow the uniform atomization droplets to connect the virtual impactor and the focusing unit and a flow path formed at the outside of the head unit to flow the sheath gas.

    ANTI-VIBRATION MOUNT
    77.
    发明公开

    公开(公告)号:US20240240689A1

    公开(公告)日:2024-07-18

    申请号:US18324414

    申请日:2023-05-26

    Inventor: Chan Jung KIM

    CPC classification number: F16F15/022 H02K5/24 H02K7/1815

    Abstract: An anti-vibration mount is proposed. The anti-vibration mount may include an upper mount including a first spring and a first damper configured to support a power generation facility from a bottom of the power generation facility that generates electricity. One end of each of the first spring and the first damper may be connected to the power generation facility, and an opposite end of each of the first spring and the first damper may be connected to a mass block that is a mass body. A lower mount provided with a second spring and a second damper to support the mass block from a bottom of the mass block. One end of each of the second spring and the second damper may be connected to the mass block that is the mass body.

    Hybrid fluid film bearing
    79.
    发明授权

    公开(公告)号:US12038047B2

    公开(公告)日:2024-07-16

    申请号:US17745979

    申请日:2022-05-17

    Inventor: Keun Ryu

    CPC classification number: F16C32/0659 F16C17/024 F16C32/0622

    Abstract: Provided is a hybrid fluid film bearing. The hybrid fluid film bearing comprises: a bearing housing installed on an outer diameter surface of a rotary shaft in the form of being coupled via a ring; a sleeve ring installed between the rotary shaft and the bearing housing, having gaps respectively with the rotary shaft and the bearing housing, and having a side in the circumferential direction opened in the radial direction; and a fixing pin connected between the bearing housing and the sleeve ring, and supported by the bearing housing so as to restrict rotation of the sleeve ring when the rotary shaft rotates. Also, the hybrid fluid film bearing may further comprise a compliant spring damper which is provided in the gap between the bearing housing and the sleeve ring and is provided as one or more bump foils.

    Companion diagnostic biomarker for anti-HER2 therapy and use thereof

    公开(公告)号:US12037646B2

    公开(公告)日:2024-07-16

    申请号:US16778237

    申请日:2020-01-31

    CPC classification number: C12Q1/6886 C12Q2600/106 C12Q2600/156 C12Q2600/158

    Abstract: A function of cyclin-dependent kinase 12 (CDK12) as a biomarker for a human epidermal growth factor receptor 2 (HER2)-positive cancer and anti-HER2 therapy, and a use of the CDK12 are provided. The CDK12 may be used for companion diagnostics of a HER2-targeted therapeutic agent for a subject having HER2+ cancer as a prognostic factor and a predictive factor for response of the subject to the anti-HER2-targeted therapeutic agent in HER2+ cancer, or used to check the probability of expressing resistance to the HER2-targeted therapeutic agent. When the CDK12 is amplified or expressed at a level higher than a reference value, the CDK12 may be suppressed to overcome the resistance to the HER2 therapeutic agent and improve a therapeutic effect, thereby improving the therapeutic efficiency of HER2-positive cancer.

Patent Agency Ranking